# Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

> **NCT01753323** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** KAF156

## Key facts

- **NCT ID:** NCT01753323
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753323, "Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01753323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*